Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy.
about
Targeting the latent reservoir to achieve functional HIV cureCardiovascular disease in human immunodeficiency virus infected patients: A true or perceived risk?Harnessing the prevention benefits of antiretroviral therapy to address HIV and tuberculosisCCR5 antagonism in HIV infection: current concepts and future opportunitiesScreening for chronic comorbid diseases in people with HIV: the need for a strategic approachThe evolving scenario of non-AIDS-defining cancers: challenges and opportunities of careHIV infection, aging, and immune function: implications for cancer risk and preventionMonocytes as regulators of inflammation and HIV-related comorbidities during cARTHIV-associated lung infections and complications in the era of combination antiretroviral therapy.Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIVDeterminants of suicide and accidental or violent death in the Australian HIV Observational DatabaseAntiretroviral drug-related liver mortality among HIV-positive persons in the absence of hepatitis B or C virus coinfection: the data collection on adverse events of anti-HIV drugs studyProspective CT screening for lung cancer in a high-risk population: HIV-positive smokersAge, comorbidities, and AIDS predict a frailty phenotype in men who have sex with menPrevalence and risk factors of poor immune recovery among adult HIV patients attending care and treatment centre in northwestern Tanzania following the use of highly active antiretroviral therapy: a retrospective study.Residual immune dysregulation syndrome in treated HIV infection.Challenges in HIV Vaccine Research for Treatment and Prevention.Mortality due to cancer among people with AIDS: a novel approach using registry-linkage data and population attributable risk methodsAntiretroviral therapy for tuberculosis control in nine African countries.Association of immunologic and virologic factors with myocardial infarction rates in a US healthcare system.Influence of the timing of antiretroviral therapy on the potential for normalization of immune status in human immunodeficiency virus 1-infected individuals.Evolving epidemiology of HIV-associated malignancies.Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational studyDevelopment of diagnostic criteria for serious non-AIDS events in HIV clinical trials.Critical illness in HIV-infected patients in the era of combination antiretroviral therapy.Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies.Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapy.Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study.Association between hepatitis B vaccine antibody response and CD4 reconstitution after initiation of combination antiretroviral therapy in HIV-infected persons.Induction of strong HIV-1-specific CD4+ T-cell responses using an HIV-1 gp120/NefTat vaccine adjuvanted with AS02A in antiretroviral-treated HIV-1-infected individuals.Cancer-Related Causes of Death among HIV-Infected Patients in France in 2010: Evolution since 2000Life expectancy of HIV-positive individuals on combination antiretroviral therapy in Canada.Dysregulated Immune Activation in Second-Line HAART HIV+ Patients Is Similar to That of Untreated Patients.Interleukin-37 Expression Is Increased in Chronic HIV-1-Infected Individuals and Is Associated with Inflammation and the Size of the Total Viral ReservoirTrends in hospital deaths among human immunodeficiency virus-infected patients during the antiretroviral therapy era, 1995 to 2011HIV pathogenesis: the host.Euphorbia Kansui Reactivates Latent HIV.Suicide risk in a representative sample of people receiving HIV care: Time to target most-at-risk populations (ANRS VESPA2 French national survey)A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256.Interleukin 10 responses are associated with sustained CD4 T-cell counts in treated HIV infection
P2860
Q26745923-6A2F0339-6D38-4E02-89C2-89F04D3870C0Q26777866-4DA105D6-9B7F-42C5-8C08-319195820D5AQ26828443-EFBE7831-095C-44F4-8D91-729C34349EDCQ26865457-ADF93ED8-FE57-4A3D-89EC-8E2FD2FE1A9EQ26866452-167DB43D-1A54-4C55-9D44-A2D8E894834EQ26991549-C2F610CD-46E2-4224-A09A-39AE3CFDA1A9Q27004165-35B81AD5-CA0B-47C3-9A22-EB0E40E98B59Q27006827-B5F09005-70C5-4FA2-9053-CD937BD4BF32Q27693307-22A524A6-73BC-4293-8E66-9E8BC92C9A46Q28079826-A27EC4A2-DC42-4F06-8A10-8F4E36549A0AQ28539917-CEB935DA-0AEA-4234-BB05-8F32A5C65F0AQ30574483-D17B3E50-B2C0-4861-93D1-68BD3846D675Q33623439-4516A225-EA0F-428A-990E-B7C7E1352BD7Q33684558-4634CAE1-743B-48D0-8F6F-571B55F836C5Q33781469-C526940A-1ADB-4A55-AE45-A4A4328AAF9AQ34020121-D7072159-2330-49FF-931E-4ACBCBC7ED7FQ34148683-64837601-BE3F-4C2B-B781-583B82E3631FQ34219254-9B33B9D1-33D6-4A51-9E72-3A5C663A715DQ34320245-96E156D2-3307-40CA-89F4-142769FE5D80Q34564981-F272C2F5-096D-40A1-877A-91D9B81792BCQ34666498-4AE3587D-F096-43E5-9980-B3A9D0F3BAF0Q34679292-ED18C9E0-9018-43BF-B14A-EB1A1970BD4DQ34903835-9722F189-143A-425B-9FC2-18571659B599Q35030752-EF5E8B76-FE5D-4A36-B72D-DEA8EBFA1697Q35095045-81EA0A97-5C1A-444D-8706-4B83C21478A8Q35169664-1AC99C1C-92A9-421E-A2D6-A2E66094DD5AQ35290298-79EC8A42-389E-4108-8BDF-B76D0FCEB8BBQ35316315-8C8BF661-082B-4384-9639-D2D64D95DCFFQ35576220-5A2368D1-8A40-41B8-AF5B-62B3B0B23D15Q35621704-377D467F-3ADB-43F7-A6E5-486C74356B22Q35666172-7BE39652-4840-4CBA-AD93-13B8085E4E4EQ35693918-2D63EBCC-B59D-44B7-8AA1-9AAEAAE5AFD9Q35873402-C389A342-08D2-4A6E-893E-35D95B900D5EQ35946786-E061B4F9-75E9-4145-9AF8-0993AC1D8C03Q36030846-E8D36678-0B69-445B-BB8D-EFE81C70B194Q36186538-C8B0F6E4-DC80-4199-B390-9E1C21189835Q36224979-61667F66-191A-41D7-A4CF-CB12B11E2A4EQ36278476-28F3F16D-38FA-43CF-85D8-BF9497DCD958Q36379230-3192E78C-34F1-489A-AAC7-54D5004D8B6AQ36379299-16072AC0-1CBA-4E36-9FEB-54A130135E65
P2860
Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Non-AIDS-defining deaths and i ...... nation antiretroviral therapy.
@ast
Non-AIDS-defining deaths and i ...... nation antiretroviral therapy.
@en
type
label
Non-AIDS-defining deaths and i ...... nation antiretroviral therapy.
@ast
Non-AIDS-defining deaths and i ...... nation antiretroviral therapy.
@en
prefLabel
Non-AIDS-defining deaths and i ...... nation antiretroviral therapy.
@ast
Non-AIDS-defining deaths and i ...... nation antiretroviral therapy.
@en
P2093
P2860
P50
P1433
P1476
Non-AIDS-defining deaths and i ...... nation antiretroviral therapy.
@en
P2093
Benoît Marin
Heiner C Bucher
Osamah Hamouda
Sarah Walker
Virginie Rondeau
P2860
P304
P356
10.1097/QAD.0B013E32832E9B78
P407
P50
P577
2009-08-01T00:00:00Z